Research into childhood acute lymphoblastic leukaemia


Leukemia is the most common cancer in children and teens, accounting for almost 1 out of 3 cancers. Most childhood leukemias are acute lymphocytic leukemia (ALL).  Chronic leukemias are rare in children.

Funded thanks to:
  • Donors
  • Total raised
    • PromoFarma clients 7.124€
  • Direct beneficiaries 1

    Those people who have naturally benefited from the project's interventions.

  • Indirect beneficiaries 400

    Those identifiable people who will potentially recieve an effect from the project's activities.

Fundación Josep Carreras contra la leucemia


  • Materials 9.000€
  • Total 9.000€


Leukemia accounts for 30% of childhood cancers and acute lymphoblastic leukemia (ALL) accounts for 85% of leukemias. 85% of patients survive ALL, despite its ravages and side effects. But 20% do not get it. The exact cause of leukemia is unknown.

The Josep Carreras Foundation carries out several research studies to improve survival from ALL and the quality of life of patients. One of the projects is led by Dr. Biola M. Javierre, which seeks to describe new therapeutic targets in acute lymphoblastic leukemia: new genes that may be involved in the development of cancer.


Research to develop treatments for childhood acute lymphoblastic leukemia (B-ALL) that generate less impact on the development of the child since the current ones have dire consequences due to their multi-organ toxicity.

Who will benefit?

Thanks to your collaboration, it will be possible to obtain the tools to sequence the complete genome of a patient: an electropheresis system for the analysis of DNA samples, a complete set of automatic pipettes and the necessary computer equipment.

Project objectives

Discover new, more effective treatments with fewer sequelae for childhood leukemia.

Updates & Links

Babies have leukemia too (video)

Josep Carreras Foundation (web)

This website uses cookies. If you continue browsing we will consider you have accepted their use . Obtain more information.